<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893306</url>
  </required_header>
  <id_info>
    <org_study_id>DMT1-MSC</org_study_id>
    <nct_id>NCT02893306</nct_id>
  </id_info>
  <brief_title>MSC Administration for the Management of Type 1 Diabetic Patients</brief_title>
  <acronym>DMT1-MSC</acronym>
  <official_title>Phase 2 Study of Intravenous Administration of Allogeneic Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad del Desarrollo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinica Alemana de Santiago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad del Desarrollo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the administration of multipotent stromal
      cell also referred as to mesenchymal stem cells (MSCs), modified Type 1 Diabetes progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: to evaluate whether a single intravenous administration of allogeneic bone
      marrow-derived multipotent stromal cell also referred as to mesenchymal stem cells (MSCs),
      modified endogenous insulin secretion capacity and exogenous insulin requirement in patients
      with Type 1 Diabetes Mellitus.

      Participants: 10, females or males, 18 years or older, diagnosed with Type 1 Diabetes
      Mellitus at most 1 year before enrollment, under exogenous insulin treatment, with pancreatic
      reserve of insulin.

      Intervention: intravenous administration of a single dose (2-3 millions/Kg) of allogeneic
      MSCs.

      Follow up: before and 1, 6, 24 months after MSC administration.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in insulin pancreatic reserve</measure>
    <time_frame>pre- and 1, 6, 24 months post-intervention</time_frame>
    <description>Levels of insulin secreted after the acute ingestion of a protein rich liquid diet</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin requirement</measure>
    <time_frame>pre- and up to 24 months post-intervention</time_frame>
    <description>Daily dose of self-administered insulin</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients with grade 3 through grade 5 adverse events (CTCAE v3.0)</measure>
    <time_frame>up to 24 months post-intervention</time_frame>
    <description>Review of patient clinical records</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with grade 3 through grade 5 adverse events (CTCAE v3.0)</measure>
    <time_frame>up to 24 months post-intervention</time_frame>
    <description>Regular communication with patient and his/her physician in order to be informed of eventual complications</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DMT1+MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>type 1 diabetic patients receiving a single dose of allogeneic ex vivo expanded mesenchymal stem cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSCs</intervention_name>
    <description>origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single</description>
    <arm_group_label>DMT1+MSCs</arm_group_label>
    <other_name>mesenchymal stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  differential diagnosis of Type 1 Diabetes

          -  diagnosed performed at most 1 year before enrollment

          -  pancreatic reserve of insulin higher than 0.8 nmol/L/h

          -  good general health status

          -  informed consent of patient

          -  consent of treating physician

          -  proved psychiatric competence to be enrolled in a clinical study

        Exclusion Criteria:

          -  pregnancy

          -  significant comorbidities

          -  HIV, HBV, HCV, HTLV-1, HLTV-2 or VDRL positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paulette Conget, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad del Desarrollo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claudio Mizon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Alemana de Santiago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Alemana de Santiago</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Ezquer F, Ezquer M, Contador D, Ricca M, Simon V, Conget P. The antidiabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment. Stem Cells. 2012 Aug;30(8):1664-74. doi: 10.1002/stem.1132.</citation>
    <PMID>22644660</PMID>
  </reference>
  <reference>
    <citation>Ezquer F, Ezquer M, Simon V, Conget P. The antidiabetic effect of MSCs is not impaired by insulin prophylaxis and is not improved by a second dose of cells. PLoS One. 2011 Jan 27;6(1):e16566. doi: 10.1371/journal.pone.0016566.</citation>
    <PMID>21304603</PMID>
  </reference>
  <reference>
    <citation>Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Ya√±ez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant. 2008 Jun;14(6):631-40. doi: 10.1016/j.bbmt.2008.01.006. Epub 2008 Apr 14.</citation>
    <PMID>18489988</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>September 1, 2016</last_update_submitted>
  <last_update_submitted_qc>September 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad del Desarrollo</investigator_affiliation>
    <investigator_full_name>Paulette Conget</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Type1 Diabetes Mellitus</keyword>
  <keyword>Multipotent stromal cell</keyword>
  <keyword>Mesenchymal stem cell</keyword>
  <keyword>Insulin</keyword>
  <keyword>Pancreatic reserve</keyword>
  <keyword>Disease progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be publish in a peer review journal</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

